Emmes, a global CRO, has acquired Institut Dr. Schauerte, a German GRO specializing in late-phase, non-interventional, and post-market clinical follow-up studies. The purchase marks Emmes’ third acquisition over the last year, after Neox and Orphan Reach.
Christine Dingivan, Emmes CEO, said, “This is another positive step in our growth and diversification strategy. Institut Dr. Schauerte has a 30-year history and deep expertise in the growing field of real-world evidence (RWE) research. Its agile, technology-enabled approach is a perfect fit with Emmes and will enhance our digital capabilities.”